In their draft guidance, the National Institute for Health and Care Excellence (NICE) said that postmenopausal women with a family history of breast cancer should now be offered the drug anastrozole, and not tamoxifen, to ...
Nov 21, 2017
0
9
Postmenopausal women with ductal carcinoma in situ (DCIS) had similar outcomes with disease recurrence whether they took tamoxifen or the aromatase inhibitor anastrozole for five years after surgery, but women in the two ...
Dec 11, 2015
0
4
The drug anastrozole is effective in treating an early form of breast cancer, according to a clinical trial led by Queen Mary University of London (QMUL). The results of the IBIS-II DCIS trial show that anastrozole is as ...
Dec 11, 2015
0
2
(HealthDay)—Extending hormone therapy by five years does not provide benefit over a two-year extension among postmenopausal women with hormone receptor-positive breast cancer who had received five years of adjuvant endocrine ...
Jul 29, 2021
0
105
(HealthDay) -- Afinitor (everolimus) has been approved in combination with the drug exemestane to treat postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer, the U.S. Food and Drug Administration ...
Jul 23, 2012
0
0
Research led by Queen Mary University of London's Wolfson Institute of Population Health has found that hormone levels, measured through blood tests, are an important indicator of whether women will benefit from recently ...
Dec 6, 2023
0
14
A comparison of three methods of predicting the risk of recurrence in women treated for estrogen-receptor (ER)-positive breast cancer finds that only the breast cancer index (BCI) – a biomarker based on the expression levels ...
Sep 11, 2013
0
0
A new analysis has provided a comprehensive comparison of scores designed to predict which women with oestrogen-receptor positive breast cancer are at high risk of recurrence beyond five years after diagnosis, and may benefit ...
May 2, 2013
0
0
